Kajalakshmy M. Phase Ii Trial Of Bevacizumab, Irinotecan, And Cetuximab In Recurrent Glioblastoma Multiforme: Efficacy, Safety And Clinical Outcomes. JRTDD [Internet]. 2022 Dec. 20 [cited 2026 Feb. 11];5(2):788-92. Available from: https://jrtdd.com/index.php/journal/article/view/3854